Damora Therapeutics, Inc. Common Stock (DMRA) was upgraded by Royal Bank Of Canada to "moderate buy".
Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $40.00 price target on the stock.
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Evercore Inc. They set an "outperform" rating and a $46.00 price target on the stock.
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors